In a report released yesterday, Asthika Goonewardene from Truist Financial maintained a Buy rating on Genmab (GMAB – Research Report), with a price target of $50.00. The company’s shares closed yesterday at $29.11.
According to TipRanks, Goonewardene is a 4-star analyst with an average return of 8.2% and a 39.81% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Compugen, ImmunoGen, and Iovance Biotherapeutics.
Genmab has an analyst consensus of Moderate Buy, with a price target consensus of $42.00, representing a 44.28% upside. In a report released on February 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
GMAB market cap is currently $18.96B and has a P/E ratio of 29.82.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genmab (GMAB) Company Description:
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
Read More on GMAB:
- Genmab price target lowered to DKK 2,400 from DKK 2,500 at RBC Capital
- Genmab price target lowered to $50 from $54 at Truist
- Transactions in connection with share buy-back program
- Notice to Convene the Annual General Meeting of Genmab A/S
- Genmab Files Annual Report with the U.S. Securities and Exchange Commission
